ArticleBMC infectious diseases2025
Mother-to-child transmission of hepatitis B virus, its associated risk factors, and the adoption of maternal antiviral therapy in eastern China: a retrospective cohort study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) mother-to-child transmission (MTCT) remains a major global public health challenge. While the World Health Organization has set ambitious targets for elimination of MTCT, achieving these goals in high-burden countries like China requires robust, real-world evaluation of preventive strategies. Our study aims to analyze the effectiveness of preventing MTCT of HBV and the associated risk factors.
methodsThis retrospective cohort study comprised 16,223 pairs of hepatitis B surface antigen-positive mothers and infants from 2021 to 2023 in geographical regions replete with coverage by preventive measures. We calculated MTCT rates of HBV in different maternal-infant groups and analyzed the risk factors associated with MTCT of HBV.
resultsThe mother-infant pairs in our study exhibited a 99.46% compliance rate for hepatitis B immunoglobulin and 98.87% for the birth-dose vaccine. The overall HBV MTCT rate was 0.60% (97/16,223). When hepatitis B viral protein (HBeAg)-positive women received timely antiviral intervention, MTCT rates were reduced to 0.48%. Multivariate analysis confirmed that HBeAg-positive (adjusted odds ratio [aOR], 132.03 [95% confidence interval {CI}, 18.26–954.41]) and HBV DNA viral load ≥ 2 × 105 IU/ml (aOR, 2.05 [95% CI, 1.30–3.22]) were associated with an increased risk for MTCT. Maternal antiviral therapy (aOR, 0.17 [95% CI, 0.10–0.28]) and infants receiving three doses of hepatitis B vaccine (aOR, 0.07 [95% CI, 0.01–0.76]) were found to be the protective factors.
conclusionsThis study provides important insights into the factors contributing to HBV MTCT. However, gaps remain with respect to adherence to antiviral therapy, the timeliness of the full-three-dose vaccination series in high-risk infants, and the standardization of treatment protocols. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.